BRW vs FUND
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BRW exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid financial fundamentals, though the absence of an Altman Z-Score limits distress risk assessment. The stock appears deeply undervalued with a current price of $6.88 versus a Graham Number of $15.63 and an intrinsic value estimate of $38.35, suggesting significant margin of safety. However, weak technical trend (0/100), declining revenue (YoY -33.10%), and poor liquidity (Quick Ratio: 0.03) offset value appeal. High dividend yield (14.78%) is notable but raises sustainability concerns given the 77.92% payout ratio and negative operating margin.
FUND exhibits a stable financial profile with a Piotroski F-Score of 6/9 and is trading at a massive discount to both its Graham Number ($20.06) and Intrinsic Value ($54.87). The valuation is exceptionally attractive with a P/E of 5.37 and a Price/Book ratio of 1.02, suggesting the market is significantly undervaluing the trust's assets. While technical trends are currently bearish (10/100) and insider activity is slightly negative, the strong dividend yield of 5.99% and sustainable payout ratio provide a significant safety buffer. The extreme earnings growth (764%) suggests a strong recovery or asset appreciation phase.
Compare Another Pair
Related Comparisons
BRW vs FUND: Head-to-Head Comparison
This page compares Saba Capital Income & Opportunities Fund (BRW) and Sprott Focus Trust, Inc. (FUND) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.